Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent cliff
Pharma
J&J's immunology portfolio compensates for Stelara's LOE
J&J's recent growth surge has come despite the LOE of Stelara. Compensating for the shortfall is Tremfya, which topped the $2 billion mark in Q2.
Kevin Dunleavy
Jul 15, 2026 11:30am
Novartis dismisses 322 more staffers based out of US headquarters
Jul 7, 2026 11:41am
How biosimilar developers are embracing next phase of US market
Jul 6, 2026 10:03am
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
Inside Astellas CEO's plan to counter Xtandi's patent cliff
Jun 11, 2026 6:00pm
Editor’s Corner: Pharma's slack tightening across pipelines, trust
Feb 9, 2026 3:00am
